AqueSys, Inc. is the first ophthalmic device company to focus exclusively on the treatment of glaucoma by re-envisioning sub-conjunctival outflow with a minimally invasive stent for the reduction of intraocular pressure. Backed by more than a decade of research and recent commercialization in European markets, the safety and efficacy of the company’s proprietary technology supports glaucoma surgeons and patients in the management of intraocular pressure to arrest the progression of vision loss associated with glaucoma. Privately held and headquartered in Southern California, AqueSys is working to change the treatment of glaucoma to benefit patients, physicians and payors around the world through the research, development, manufacturing and commercialization of its minimally invasive glaucoma stents. Additional information about the XEN Gel Stent can be found at www.aquesys.com.
View Top Employees from AqueSys, IncWebsite | https://www.aquesys.com |
Revenue | $1 million |
Funding | $90.6 million |
Employees | 4 (3 on RocketReach) |
Founded | 2006 |
Phone | (949) 450-0250 |
Fax | (949) 450-0249 |
Technologies |
JavaScript,
HTML,
Bootstrap
+4 more
(view full list)
|
Industry | Medical Devices, Medical Devices & Equipment, Medical Device, Ophthalmology, Manufacturing, Retail, Health Care, Glaucoma |
Competitors | AcuFocus, Inc., BVI Medical, ClarVista Medical, Implandata Ophthalmic Products |
SIC | SIC Code 504 Companies, SIC Code 50 Companies |
NAICS | NAICS Code 42 Companies, NAICS Code 423 Companies |
Looking for a particular AqueSys, Inc employee's phone or email?
The AqueSys, Inc annual revenue was $1 million in 2023.
Roger Kash is the Director of Professional Education of AqueSys, Inc.
3 people are employed at AqueSys, Inc.
AqueSys, Inc is based in Irvine, California.
The NAICS codes for AqueSys, Inc are [42, 423].
The SIC codes for AqueSys, Inc are [504, 50].